Skip to main content

Table 2 Acute-phase protein plasma levels in COVID-19 patients compared to healthy controls (mg/dl), except for ACT and SAA (µg/ml)

From: Plasma markers of COVID-19 severity: a pilot study

APP

COVID-19

n

Healthy controls

n

p-value

ACT

1437 (1356–1626)

20

1579 (1484–1856)

9

p = 0.066

SAA

49.33 (45.30–52.81)

20

54.69 (47.43–70.33)

8

p = 0.104

AGP

167.0 (124.5–209.8)

20

68.9 (57.2–82.2)

10

p < 0.001

HP

271.5 (189.3–335.8)

20

71.4 (43.5–104.0)

10

p < 0.001

AAT

235.5 (180.3–270.0)

20

127.5 (119.3–139.5)

10

p < 0.001

hs-CRP

9.680 (4.123–18.925)

20

0.185 (0.063–0.827)

10

p < 0.001

A2MG

112.5 (108.0–154.8)

20

128.5 (111.5–200.3)

10

p = 0.243

CP

41.1 (35.7–52.5)

20

28.95 (23.7–35.18)

10

p = 0.001

ALB

2540 (1915–3135)

20

4390 (3918–4833)

10

p < 0.001

  1. Data presented as median and interquartile range (IQR)
  2. A2MG alpha2-macroglobulin, AAT alpha1-antitrypsin, ACT alpha 1-antichymotrypsin, AGP alpha-1 acid glycoprotein, ALB albumin, CP ceruloplasmin, hs-CRP high sensitivity C-reactive protein, HP haptoglobin, SAA serum amyloid A. Two-sided p-values were calculated with Mann–Whitney-U test, bold highlights statistical significance